John Cini
Founder chez SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Fortune : 3 404 $ au 31/03/2024
Profil
John K.
Cini is the founder of Sonnet BioTherapeutics, Inc. (founded in 2015) and Sonnet BioTherapeutics Holdings, Inc. (founded in 2011).
At Sonnet BioTherapeutics, Inc., he holds the title of Chief Scientific Officer since 2015, and at Sonnet BioTherapeutics Holdings, Inc., he holds the title of Chief Scientific Officer since 2020.
Dr. Cini's former jobs include Executive Director at Medarex, Inc. and Vice President-Discovery & Development Sciences at Outlook Therapeutics, Inc. (2011-2015).
Dr. Cini earned a doctorate degree from the University of North Texas.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/12/2023 | 1 830 ( 0,06% ) | 3 404 $ | 31/03/2024 |
Postes actifs de John Cini
| Sociétés | Poste | Début |
|---|---|---|
| SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Founder | 01/01/2011 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Founder | 01/01/2015 |
Anciens postes connus de John Cini
| Sociétés | Poste | Fin |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2015 |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Director/Board Member | - |
Formation de John Cini
| University of North Texas | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Health Technology |
